The evolving role of tiotropium in asthma

REVIEW

• Abstract
• Fulltext
• Metrics
• Get Permission

Emma R McIvor,¹ R Andrew McIvor^2
1Queen’s University, Belfast, UK; ²Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada

Abstract: Tiotropium is a long-acting muscarinic antagonist (LAMA) that exerts its bronchodilatory effect by blocking endogenous acetylcholine receptors in the airways. Its safety and efficacy are well established for the treatment of COPD, and it is now being recognized for its role in improving lung function and control in asthma. This review discusses the evolving role of tiotropium delivered by the Respimat^® in patients across the range of asthma severities and ages, and provides an overview of safety and efficacy data.

Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome

Allergy, Asthma & Clinical Immunology

SHORT REPORT

 

OPEN ACCESS

• Hermenio LimaEmail authorView ORCID ID profile,
• Melinda Gooderham,
• Jan Dutz,
• Charles Lynde,
• Hugo Chapdelaine,
• Anne Ellis,
• Martin Gilbert,
• Vincent Ho,
• Kim Papp,
• Yves Poulin and
• Gordon Sussman

Allergy, Asthma & Clinical Immunology201713:38

https://doi.org/10.1186/s13223-017-0210-0

©  The Author(s) 2017

Abstract

Background

Treat-to-target therapy approaches are established for chronic diseases such as diabetes, hypertension, and more recently rheumatoid arthritis, resulting in improved patient outcomes. These approaches do not use patient reported outcomes (PRO) as targets of therapy. Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria (CIU), is defined as recurrent urticaria of known and unknown cause, lasting more than 6 weeks. Treatment of CSU can be challenging. However, with the advent of proven therapies and validated instruments for measuring disease activity, the concept of treat-to-target (T2T) can be successfully applied to CSU. Herein, we propose a potential PRO therapeutic target and suggest a T2T approach for the management of patients with CSU.

Could Eosinophilia predict clinical severity in nasal polyps?

Multidisciplinary Respiratory Medicine 

ORIGINAL RESEARCH ARTICLE

OPEN ACCESS

• Figen Aslan,
• Eren AltunEmail author,
• Serpil Paksoy and
• Gulay Turan

Multidisciplinary Respiratory Medicine201712:21

https://doi.org/10.1186/s40248-017-0102-7

©  The Author(s). 2017

Abstract

Background

Although nasal polyps are one of the most frequent diseases, their etiopathogenesis remains unclear.Since eosinophils are the main inflammatory cells in the substantial proportion of nasal polyp tissues, they are considered potentially responsible for the etiopathogenesis and prognosis of the disease. Aim of this study was to investigate the relation between mucosal and peripheral eosinophilia and their relation with disease severity in nasal polyps.

The history and epidemiology of Middle East respiratory syndrome corona virus

Multidisciplinary Respiratory Medicine

REVIEW

 

OPEN ACCESS

Aisha M. Al-Osail 

and

Marwan J. Al-Wazzah

Multidisciplinary Respiratory Medicine 2017 12:20

https://doi.org/10.1186/s40248-017-0101-8\

Abstract

Corona viruses cause common cold, and infections caused by corona viruses are generally self-resolving. During the last 4 years, corona viruses have become the most important viruses worldwide because of the occurrence of several recent deaths caused by corona viruses in Saudi Arabia. Spread of the infection occurred worldwide; however, most cases of mortality have occurred in the Middle East.

Small airway bronchodilator response to different doses of salbutamol in 7-year-old children

Respiratory Research 

LETTER TO THE EDITOR

 

OPEN ACCESS

• Dong Keon Yon,
• Hye Mi Jee,
• Eun Kyo Ha,
• Seung Jin Lee,
• Young-Ho Jung,
• Kyung Suk LeeEmail author and
• Man Yong HanEmail author

Respiratory Research201718:148

https://doi.org/10.1186/s12931-017-0632-8

Abstract

The Global Initiative for Asthma (GINA) guidelines do not specify a bronchodilator range for bronchodilator response (BDR) testing and simply recommend a salbutamol dose of 200 to 400 μg.

Asthma referrals: a key component of asthma management that needs to be addressed

Journal of Asthma and Allergy Volume 2017:10 Pages 209—223

David Price, Leif Bjermer, David A Bergin, Rafael Martinez

¹Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK; ²Observational and Pragmatic Research Institute, Singapore; ³Department of Respiratory Medicine and Allergology, Lund University, Lund, Sweden; ⁴Novartis Ireland Limited, Dublin, Ireland; ⁵Novartis Pharma AG, Basel, Switzerland

Abstract: Heterogeneity of asthma and difficulty in achieving optimal control are the major challenges in the management of asthma. To help attain the best possible clinical outcomes in patients with asthma, several guidelines provide recommendations for patients who will require a referral to a specialist.

Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews

Clinical and Translational Allergy

REVIEW

OPEN ACCESS

• Felix Asamoah†,
• Artemisia Kakourou†,
• Sangeeta DhamiEmail authorView ORCID ID profile,
• Susanne Lau,
• Ioana Agache,
• Antonella Muraro,
• Graham Roberts,
• Cezmi Akdis,
• Matteo Bonini,
• Ozlem Cavkaytar,
• Breda Flood,
• Kenji Izuhara,
• Marek Jutel,
• Ömer Kalayci,
• Oliver Pfaar and
• Aziz Sheikh

†Contributed equally

Clinical and Translational Allergy20177:25

https://doi.org/10.1186/s13601-017-0160-0

Abstract

Background

There is clinical uncertainty about the effectiveness and safety of allergen immunotherapy (AIT) for the treatment of allergic asthma.

Science, lifestyle, and human health: Challenging trilogy for the allergist/immunologist

• Allergy Asthma Proc
• PMC4929231

Allergy and Asthma Proceedings

Allergy Asthma Proc. 2016 Jul-Aug; 37(4): 265–267.

doi:  10.2500/aap.2016.37.3973 PMCID: PMC4929231

Joseph A. Bellanti, M.D. and Russell A. Settipane, M.D.

We live in a world awash with foreign substances, some inanimate and others, living microbes, in soil, water, and air that are potentially inimical to human health. Throughout evolution, deep seas and high peaks have long provided niches for these substances that are harsh yet permissive for the human species to both adapt to as well as to exploit not only by overwhelming them but at times by profiting from them and by yielding profit in return. Plants and animals, humans among them, for example, have had to cope with bacteria and parasites from the beginning stages of multicellular evolution due to the simple fact that they were here first. Successful adaptation to these foreign agents comprises the classic expressions of protective immunity....

Formats:

• Article
 | 
• PubReader
 | 
• ePub (beta)
 | 
• PDF (36K)
 | 
• Citation